Hints and tips:
...Mr Gal says sales are also being driven by strong international demand from eastern Europe and Asia, especially South Korea....
...Nycomed, a privately held business with a presence in Russia and Brazil, will expand into China with the purchase of 51.3 per cent of Guangdong Techpool Bio-Pharma for $214m....
...Operating margins of about 18 per cent are also below the 25 per cent typical of a speciality pharma company. So what does Abbott see in the business? Earnings, for one....
...Solvac, Solvay’s largest controlling shareholder that holds the Solvay family’s 30 per cent stake, is understood to have approved the sale of the pharma business, which began in April....
...The pharma business had revenue last year of €2.7bn, or 28 per cent of the company’s total sales of €9.49bn....
...Solvay retained a string of investment banks this year to explore options for the pharma division and attracted preliminary interest from several large pharmaceuticals companies before many dropped out....
International Edition